We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cantabio Pharmaceuticals Inc (CE) | USOTC:CTBO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.01 | 0.00 | 01:00:00 |
X
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2016
|
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to __________________
|
|
|
|
Delaware
|
000-54905
|
99-0373067
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
1250 Oakmead Pkwy
Sunnyvale, California
(Address of principal executive offices)
|
|
94085
(Zip Code)
|
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
X
|
|
|
|
||
PART I - FINANCIAL INFORMATION
|
|
|
||
|
|
|
||
Item 1.
|
|
|||
|
|
|
||
|
2
|
|||
|
|
|
||
|
3
|
|||
|
4
|
|||
|
|
|
||
|
5
|
|||
|
|
|
||
Item 2.
|
8
|
|||
|
|
|
||
Item 3.
|
9
|
|||
|
|
|
||
Item 4.
|
9
|
|||
|
|
|
||
PART II – OTHER INFORMATION
|
|
|
||
|
|
|
||
Item 1.
|
10
|
|||
|
|
|
||
Item 1A.
|
10
|
|||
|
|
|
||
Item 2.
|
10
|
|||
|
|
|
||
Item 3.
|
10
|
|||
|
|
|
||
Item 4.
|
10
|
|||
|
|
|
||
Item 5.
|
10
|
|||
|
|
|
||
Item 6.
|
10
|
|||
|
|
|
||
SIGNATURES
|
|
11
|
|
September 30,
|
March
31,
|
||||||
|
2016
|
2016
|
||||||
|
||||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
12,629
|
$
|
52,110
|
||||
Total Current Assets
|
12,629
|
52,110
|
||||||
|
||||||||
TOTAL ASSETS
|
$
|
12,629
|
$
|
52,110
|
||||
|
||||||||
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)
|
||||||||
Current labilities
|
||||||||
Accounts payable and accrued expenses
|
257,137
|
225,498
|
||||||
Accrued technology access fee
|
189,669
|
173,414
|
||||||
Due to officers
|
-
|
6,420
|
||||||
Note payable to related party
|
10,022
|
16,562
|
||||||
TOTAL LIABILITIES
|
$
|
456,828
|
$
|
421,894
|
||||
|
||||||||
Stockholders' Equity (Deficit)
|
||||||||
Common stock, $0.001 par value, (250,000,000 shares authorized 26,805,270 shares issued and outstanding as of September 30, 2016 and March 31, 2016)
|
26,805
|
26,805
|
||||||
Stock subscriptions
|
985,000
|
500,000
|
||||||
Additional paid in capital
|
99,324
|
99,324
|
||||||
Accumulated deficit
|
(1,555,328
|
)
|
(995,913
|
)
|
||||
Total Stockholders' Equity (Deficit)
|
(444,199
|
)
|
(369,784
|
)
|
||||
TOTAL LIABILITIES & STOCKHOLDERS' (DEFICIT)
|
$
|
12,629
|
$
|
52,110
|
|
||||||||||||||||
|
||||||||||||||||
|
For the three months ended September 30,
|
For the six months ended September 30,
|
||||||||||||||
|
2016
|
2015
|
2016
|
2015
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Research & development
|
$
|
69,070
|
$
|
2,326
|
$
|
181,802
|
$
|
2,326
|
||||||||
General & administrative
|
218,521
|
150,231
|
372,849
|
244,781
|
||||||||||||
Total operating expenses
|
287,591
|
152,557
|
554,651
|
247,107
|
||||||||||||
Loss from operations
|
(287,591
|
)
|
(152,557
|
)
|
(554,651
|
)
|
(247,107
|
)
|
||||||||
Other income (expense):
|
||||||||||||||||
Interest expense
|
(3,995
|
)
|
-
|
(7,864
|
)
|
-
|
||||||||||
Foreign currency transaction gain (loss)
|
(1,962
|
)
|
(1,738
|
)
|
3,100
|
(6,614
|
)
|
|||||||||
Total other expense, net
|
(5,957
|
)
|
(1,738
|
)
|
(4,764
|
)
|
(6,614
|
)
|
||||||||
|
||||||||||||||||
Net loss
|
$
|
(293,548
|
)
|
$
|
(154,295
|
)
|
$
|
(559,415
|
)
|
$
|
(253,721
|
)
|
||||
|
||||||||||||||||
Net loss per share - basic and diluted
|
$
|
(0.01
|
)
|
$
|
(0.01
|
)
|
$
|
(0.02
|
)
|
$
|
(0.02
|
)
|
||||
|
||||||||||||||||
Weighted average shares outstanding, basic and diluted
|
26,805,000
|
14,824,000
|
26,805,000
|
14,824,000
|
||||||||||||
|
Six months ended
|
||||||||
|
September 30,
|
September 30,
|
||||||
|
2016
|
2015
|
||||||
Cash Flows From Operating Activities
|
||||||||
Net loss
|
$
|
(559,415
|
)
|
$
|
(253,721
|
)
|
||
Adjustments to reconcile net loss to cash used in operating activities:
|
||||||||
Gain on foreign currency translation
|
(1,234
|
)
|
-
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts payable and accrued expenses
|
31,638
|
63,920
|
||||||
Accrued technology access fee
|
16,256
|
-
|
||||||
Prepaid expenses
|
-
|
(4,253
|
)
|
|||||
Due to officers
|
(6,420
|
)
|
1,151
|
|||||
Net cash used in operating activities
|
(519,175
|
)
|
(192,903
|
)
|
||||
Cash Flows From Financing Activities
|
||||||||
Proceeds from notes payable related party
|
10,022
|
34,178
|
||||||
Repayment to notes payable related party
|
(15,328
|
)
|
(36,800
|
)
|
||||
Stock subscriptions
|
485,000
|
250,000
|
||||||
Net cash provided by financing activities
|
479,694
|
247,378
|
||||||
Net increase (decrease) in cash
|
(39,481
|
)
|
54,475
|
|||||
|
||||||||
Cash at beginning of period
|
52,110
|
209
|
||||||
Cash at end of period
|
$
|
12,629
|
$
|
54,684
|
Expense recognized in the 3 months to
September 30, 2016
|
Expense recognized in
the 6 months to
September 30, 2016
|
Accounts payable
at September 30, 2016
|
||||||||||
Fees
|
Fees
|
|||||||||||
Toth and Associates, LTD
|
$
|
36,000
|
$
|
72,000
|
$
|
62,000
|
||||||
Capro, LTD
|
$
|
30,000
|
$
|
60,000
|
$
|
60,000
|
||||||
Eden Professional, LTD
|
$
|
19,000
|
$
|
38,000
|
$
|
56,000
|
||||||
Total
|
$
|
85,000
|
$
|
170,000
|
$
|
178,000
|
None
|
31.1
|
Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
|
31.2
|
Certification of Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
|
32.1
|
Certification of the Principal Executive Officer and Acting Principal Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
32.2
|
Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
1 Year Cantabio Pharmaceuticals (CE) Chart |
1 Month Cantabio Pharmaceuticals (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions